PharmaSources/1℃June 19, 2020
Tag: Breakthrough Therapy , Type 2 Immune Indications , Dupilumab , Sanofi
Sanofi explained in detail the mechanism of action of Dupilumab and its clinical benefit in type 2 immune indications at a recent R&D conference. Dupilumab targets IL4Ra, which can simultaneously block IL4, IL13-mediated cell differentiation and inflammation. The potential indications are type 2 immunity such as atopic dermatitis, asthma, and nasal-nasal polyps. Compared with JAKi, anti-IgE antibodies, and IL-13 therapy, the drug has a wider range of indications.
Up to now, Dupilumab has got 5 indications in the United States, including 3 with atopic dermatitis, which has covered patients over 6 years old. In the future, Dupilumab will continue to expand in patients with atopic dermatitis under 6 years old, the earliest date is expected to be in 2022.
Dupilumab can improve skin damage, itching symptoms and quality of life in patients with atopic dermatitis, and improve evaluation indicators such as EASI-50 and NRS. At the same time, the drug has good safety and tolerability.
It is expected that Dupilumab to be approved for marketing in China in the next few weeks!
Reference:
Sanofi Official Website
-----------------------------------------------------------------------
Editor's Note:
To become a freelance writer of PharmaSources.com,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@imsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: